KTTA NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Pasithea Therapeutics Corp · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 0.46 USD
1.1% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -35.1% below the Trend Line and sits at 10.1% of its 52-week range. The latest completed week returned 1.1%, after a -16.4% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 54/100. Near-term considerations: volume confirmation is below normal; earnings are due in 11d.

Setup score 15 out of 100
Latest Close 0.46 USD 31 Jul 2026
1W Return 1.1% latest completed week
4W Return -16.4% short-term follow-through
12W Return -42.2% quarterly tape
Trend Breadth 17.3% 9 of 52 weeks active
Volume Ratio 0.5x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 1.1% Latest completed week; four-week move -16.4%. Indicator stack 10/28 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 40.64% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 54/100 52 relevant articles in the latest sentiment read. Event risk 11d Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -35.1% below the Trend Line and sits at 10.1% of its 52-week range. The latest completed week returned 1.1%, after a -16.4% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.5x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0812-week average 0.17

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure3/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.08Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -16.4% over four weeks, -42.2% over 12 weeks, and -34.1% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W1.1%
4W-16.4%
12W-42.2%
26W-46.6%
52W-34.1%
Active trend streak0 weeks
Active weeks in one year9
Trend breadth17.3%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-1.12Latest activity-pressure read.
Pressure change-19.1%Four-week change in activity pressure.
Leadership-45.62Latest relative-leadership reading.
RS change-15.4%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 61% Model confidence 58%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength45/100Blend of value, momentum, and quality. Underlying universe rank 56; rank 1 is best.
Value47/100Relative valuation strength. Underlying universe rank 54; rank 1 is best.
Quality46/100Profitability and accounting quality. Underlying universe rank 55; rank 1 is best.
Momentum47/100Medium-term price momentum. Underlying universe rank 54; rank 1 is best.
Growth47/100Revenue and earnings growth. Underlying universe rank 54; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-111.4%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-362.1%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-
Net share repurchases relative to market value.
Shareholder yield
-
Dividend yield plus net buyback yield.
Net debt / EBITDA
2.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity8 / 0

8 acquisitions and 0 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment54/100

Weighted news tone is neutral across 52 relevant articles.

15 positive · 32 neutral · 5 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings11dNext report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-77.7%Distance below the 52-week high.
13-week volatility7.6%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher12 of 2614 weeks finished lower.
Best week+21.9%Week of 1 May.
Worst week-18.2%Week of 5 Jun.
Latest week+1.1%Week of 31 Jul.

Shape of recent returns

Strong gains6
Modest gains6
Flat weeks0
Modest losses3
Sharp losses11
Recent vol7.6%13-week weekly-return volatility.
Base vol57.0%52-week weekly-return volatility.
Up/down split21/30Count of positive and negative weeks in the 52-week window.
Average skew25.2% / -9.2%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape17/100

Trend, activity pressure, participation, and risk combine to a 17/100 tape read.

 Indicator analysis15/100

Latest 12-week confirmation: trend 0/12, activity pressure 3/12, relative leadership 0/12.

Activity pressure 0.08; No reversal markers Next-Week ExpectancyNegative 40.64%

Next-week expectancy is negative with a 40.64% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors45/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 50 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment54/100

Weighted news tone is neutral across 52 relevant articles.

Pasithea Therapeutics (NASDAQ: KTTA) sets virtual 2026 meeting and reverse split vote Insiders8 / 0

8 acquisitions and 0 disposals in the latest 180-day insider tape.

 Earnings11d

Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20260.46 USD1.1%0.71 USD3.52 USD-1.12-45.621.8MOff
24 Jul 20260.46 USD1.1%0.73 USD3.60 USD-1.00-46.412.4MOff
17 Jul 20260.45 USD-8.6%0.75 USD3.67 USD-0.97-48.341.5MOff
10 Jul 20260.49 USD-10.4%0.78 USD3.75 USD-0.97-46.351.3MOff
3 Jul 20260.55 USD1.2%0.80 USD3.81 USD-0.94-39.5328.2MOff
26 Jun 20260.54 USD8.7%0.82 USD3.86 USD-0.98-40.221.4MOff
19 Jun 20260.50 USD-15.4%0.85 USD3.92 USD-0.73-47.951.7MOff
12 Jun 20260.59 USD1.0%0.84 USD3.98 USD-0.46-37.52994.3KOff
5 Jun 20260.58 USD-18.2%0.85 USD4.04 USD-0.11-37.363.3MOff
29 May 20260.72 USD2.2%0.85 USD4.09 USD0.14-27.743.2MOff
22 May 20260.70 USD-10.3%0.85 USD4.14 USD0.23-28.201.1MOff
15 May 20260.78 USD-1.9%0.85 USD4.18 USD0.09-19.921.2MOff
8 May 20260.80 USD-5.4%0.85 USD4.22 USD-0.12-19.461.6MOff
1 May 20260.84 USD21.9%0.85 USD4.26 USD-0.40-10.882.5MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.